These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 15997843

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics.
    Gao C, Zhang H, Guo Z, You T, Chen X, Zhong D.
    Drug Metab Dispos; 2012 Oct; 40(10):2009-20. PubMed ID: 22822035
    [Abstract] [Full Text] [Related]

  • 25. First-pass metabolism of 5-fluorouracil in rats.
    Yuasa H, Gu J, Hayashi Y, Watanabe J.
    J Pharm Pharmacol; 1998 Sep; 50(9):1019-25. PubMed ID: 9811163
    [Abstract] [Full Text] [Related]

  • 26. [Study on the pharmacokinetics of scutellarin in dogs].
    Jiang XH, Li SH, Lan K, Yang JY, Zhou J.
    Yao Xue Xue Bao; 2003 May; 38(5):371-3. PubMed ID: 12958843
    [Abstract] [Full Text] [Related]

  • 27. Hepatic, gastric and intestinal first-pass effects of vitexin-2''-O-rhamnoside in rats by ultra-high-performance liquid chromatography.
    Gao Y, Du Y, Ying Z, Leng A, Zhang W, Meng Y, Li C, Xu L, Ying X, Kang T.
    Biomed Chromatogr; 2016 Feb; 30(2):111-6. PubMed ID: 26031900
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. [The synthesis, characterization and in situ intestinal absorption of different molecular weight scutellarin-PEG conjugates].
    Zhou Q, Jiang X, Li K, Fan X.
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2006 Apr; 23(2):353-6, 387. PubMed ID: 16706365
    [Abstract] [Full Text] [Related]

  • 30. First-pass metabolism of omeprazole in rats.
    Watanabe K, Furuno K, Eto K, Oishi R, Gomita Y.
    J Pharm Sci; 1994 Aug; 83(8):1131-4. PubMed ID: 7983597
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Low oral bioavailability and pharmacokinetics of senkyunolide a, a major bioactive component in Rhizoma Chuanxiong, in the rat.
    Yan R, Lin G, Ko NL, Tam YK.
    Ther Drug Monit; 2007 Feb; 29(1):49-56. PubMed ID: 17304150
    [Abstract] [Full Text] [Related]

  • 33. Effect of ion-pairing and enhancers on scutellarin skin permeability.
    Wang M, Fang L, Ren C, Li T.
    J Pharm Pharmacol; 2008 Apr; 60(4):429-35. PubMed ID: 18380914
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Gastrointestinal first-pass effect of YJA-20379-8, a new reversible proton pump inhibitor, in rats.
    Kim J, Kim EJ, Han KS, Chang MS, Lee MG.
    J Pharm Pharmacol; 1999 Sep; 51(9):1031-6. PubMed ID: 10528986
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Synthesis, characterization and in situ intestinal absorption of different molecular weight scutellarin-PEG conjugates.
    Zhou Q, Jiang X, Li K, Fan X.
    Pharmazie; 2006 Aug; 61(8):660-3. PubMed ID: 16964704
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Nanosuspension development of scutellarein as an active and rapid orally absorbed precursor of its BCS class IV glycoside scutellarin.
    Yang X, Miao X, Cao F, Li S, Ai N, Chang Q, Lee SMY, Zheng Y.
    J Pharm Sci; 2014 Nov; 103(11):3576-3584. PubMed ID: 25187229
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.